Introduction
Since the discovery that mouse melanoma cell activities are influenced by melanotropins (melanocyte-stimulating hormones [MSH]') (1) , much interest has been focused on the biological actions and potential clinical value of MSH in human melanoma. Several treatment strategies are currently being developed that aim to exploit the interaction of alpha-MSH with its receptors on melanoma cells. These agents are designed to kill the cells either directly, using MSH-toxin hybrid molecules (2, 3), or indirectly, by targeting the cells for T cell-mediated destruction using MSH (anti-CD3 receptor) conjugates (4) . The clinical potential of these approaches is critically dependent on the presence of functional alpha-MSH receptors on human melanoma cells in vivo. However, while animal melanoma cell lines have long been known to respond to MSH (1) and have recently been shown to express MSH receptors in vitro (5) (6) (7) and in situ (5) , the frequency with which MSH receptors are expressed in human melanomas is unknown.
Metabolic effects of MSH have been detected in some cultured human melanoma cell lines (8, 9) . Earlier attempts to detect alpha-MSH binding sites in cultured human melanoma cells were inconclusive (9, 10) , but one group has recently confirmed the presence of an MSH binding protein with the use of biologically active MSH tracer peptides (1 1, 12) . Nevertheless, it is not clear to what extent the behavior of tumor cells in culture reflects that in vivo, since cultured melanocytic cells have been shown to express an altered profile of cell surface proteins such as growth factor receptors, as compared with the corresponding cells in situ ( 13) .
To assess the potential biological roles of endogenous melanotropins in human melanoma and the potential therapeutic value of MSH receptor-targeted agents, we designed these studies to determine the presence or absence and the binding properties of melanotropin receptors in human melanoma cells in situ. We have recently developed methods for the characterization of MSH receptors in cultured B 16 mouse melanoma cells in vitro and in tumor tissue in situ (5, 14) using a radiolabeled MSH tracer that has full biological activity and potency (14) , and is known to detect functional MSH receptors (5) . The results, recently presented in preliminary form (15) Preparation of['25I]NDP-MSH. NDP-MSH was iodinated and purified as described (14) . Briefly, 4 Mug peptide was iodinated using Enzymobeads (Bio-Rad Laboratories, Richmond, CA) and purified by reverse-phase chromatography. Fractions were pooled from the portion ofthe eluted peak showing greatest immunoreactivity and specific activity (typically 1.2-2.0 X 106 Ci/mol). This material has consistently shown biological activity (stimulation of melanogenesis) virtually identical to that of uniodinated NDP-MSH in B16 mouse melanoma cells (14) .
In situ binding studies. Serial slide-mounted, dried, unfixed frozen tissue sections were preincubated for 15 min at 230C in a buffer consisting of 50 mM Tris-HCI, 140 mM NaCl, 2.5 mM CaCl2, and 1.2 mM MgCI2, pH 7.2. Matched sets of serial sections were then incubated for 60 min in a similar buffer with the addition of BSA (0.25%).
ascorbic acid (0.6%), aprotinin (500 KIU/ml), (Fig. 4) . Alpha-MSH and NDP-MSH were of comparable potency overall (approximate EC50 = 1-2 X 10-9 M) in inhibiting ['251]NDP-MSH binding (Fig. 4 A) , whereas ACTH was less potent (Fig. 4 B) . In contrast, the nonmelanotropic peptides substance P (10-6 M) and somatostatin (10-6 M), used as controls, did not inhibit tracer binding to tumor cells in tissue sections of the same series (Table I ). None of the tested peptides inhibited tracer localization in inflammatory tissue.
Prevalence ofMSH receptor expression in metastatic melanoma patients. To determine the prevalence of specific melanotropin binding site expression, the relative intensity of specific binding in different patients was assessed by image analysis of film autoradiograms. The data were obtained from three separate experiments. In each experiment, melanoma specimens of known receptor-positive patients, and in some cases specimens of known receptor-positive mouse melanomas as well (5) (1, 5-7, 14, 19) , the actions of melanotropins in human melanoma are poorly understood. Varying effects of MSH on cultured human melanoma cell tyrosinase activity (8, 9) have been reported. MSH also induces cytoplasmic granule accumulation (20) and stimulates cyclic AMP accumulation in some human melanoma cultures (9) as well as in normal melanocytes (21) . Characterization of human MSH receptors has been impossible until very recently, since valid methodologies for their detection have been unavailable. In earlier studies using either immunocytochemical methods (9) or radiolabeled alpha-MSH (10), MSH binding was detected, but the reports failed to document whether the binding was specific (9) or whether the MSH tracer was biologically active (10) . More recently, a specific MSH binding protein has been detected in cultured human cell lines with the use of biologically active photolabeled (11) and radiolabeled (12) alpha-MSH derivatives.
Like the MSH receptor of B16 mouse melanoma cells (5-7) and tumors (5) , that of human melanomas in situ shows high apparent affinities for melanotropins (nanomolar range). The relative potencies of the peptides in human melanoma (14), it is not known whether cells of nonmelanocytic tissues of humans express MSH receptors. In mice, alpha-MSH has immunomodulatory effects on certain lymphoid targets, whereas NDP-MSH does not (22, 23) . This suggests that multiple melanotropin receptor subclasses may exist, since NDP-MSH is a superpotent melanotropin agonist in melanocytic cells (24 (25) (26) (27) , control ofcell shape (28) , and growth (29) (30) (31) (32) . Alpha-MSH also stimulates proliferation in A375 human melanoma cells (26) , in a panel of human melanoma cell lines (33) , and in cultured normal human melanocytes (34). It will therefore be of interest to determine 1830 Tatro In postulating a role of endogenous melanotropins in control of melanoma cell behavior, it is implicit that tumor cells must be exposed to melanotropins in vivo. In fact, the gene encoding the melanotropin precursor, proopiomelanocortin, is expressed in diverse nonpituitary sites, including lymphoid cells and malignant tumors (35-37). Thus, although alpha-MSH and ACTH normally circulate in the blood ofhumans at only low picomolar concentrations (37, 38) , locally produced melanotropins may have significant biological effects. Full assessment of the potential roles of endogenous melanotropins will require determination of which additional processed forms of MSH are present locally or in the circulation, and testing of their effects in melanoma bioassay systems.
The actions of endogenous melanotropins on melanoma may be modulated by interactions with cytokines and the local environment. Interferons, which are present locally and may participate in immune responses to melanoma (39) , enhance MSH responses and receptor expression in mouse melanoma cells (40) . Moreover, the actions of IL-1, a cytokine that is directly toxic to melanoma cells (41) , are antagonized by alpha-MSH in multiple target tissues (18, 19, 42) , possibly through a postreceptor mechanism (43) . The presence of melanotropin receptors in melanoma thus raises the possibility that melanotropins may affect melanoma cell survival by modulating the actions of cytokines on melanoma cells. Conversely, epidermal-derived thymocyte activating factor, a cytokine-like factor in skin which is highly related to IL-1 (44) , antagonizes MSH action in S91 mouse melanoma cells (45) . In mouse melanoma cells laminin (46) and collagen (30) augment responsiveness to MSH, suggesting a role ofthe extracellular matrix in controlling melanotropin responsiveness. Together, the available evidence suggests that melanoma cells may be influenced in vivo by complex and bidirectional interactions between melanotropins, substratum, and immune mediators produced in lymphoid cells and skin, a feature not predicted from earlier in vitro studies.
Several groups have undertaken the development of MSH receptor-targeted agents as potential therapeutic tools for treatment of malignant melanoma (2) (3) (4) . The present results support the premise of these strategies, since the majority of human metastatic melanomas appear to express detectable specific binding sites, but also indicate that some patients would not be candidates for these therapies. Since MSH receptors are found in some tumors but not in all, the in situ binding assay may be an effective method with which to evaluate patients as candidates for treatment with MSH-linked hybrid therapeutic agents, and to identify other potential sites of toxicity. In situ localization is critical, since the nonspecific binding associated with necrotic and inflammatory tissues may obscure the presence of specific MSH receptors if specimens are assayed by other methods.
In summary, the detection of specific melanotropin receptors in metastatic melanoma in situ raises new questions about the biological roles of proopiomelanocortin-derived peptides in human melanoma. It also increases the likelihood that hybrid MSH-linked therapeutic agents would be useful in the treatment of certain melanoma patients, and provides a potential approach for screening of candidate patients for such therapies. It will be of interest to determine whether normal epidermal melanocytes and cells ofother stages ofmelanocytic tumor progression, such as nevus melanocytes and primary melanoma (13) , share the property of MSH receptor expression, and to define the factors that regulate receptor expression and function.
